Buy 5 or More Products! Save 25% On Total.
 Buy 3 or More Products! Save 10% On Total.
 Free Shipping! No Minimum Order.

Which of the following shall be measured before initiating Inspra therapy?
 
a. blood glucose level
b. amino acid (alanine) level
c. serum potassium level
d. INR ratio
e. LDL level
 
Answer: Serum potassium level. Eplerenone (Inspra) is a blocker of aldosterone binding at the mineralocorticoid receptor. It is available for oral administration contains 25 mg or 50 mg of Eplerenone (Inspra). It is indicated for the treatment of Congestive Heart Failure Post-Myocardial Infarction and Hypertension.
 
Treatment should be initiated at 25 mg once daily and titrated to the recommended dose of 50 mg once daily, preferably within 4 weeks as tolerated by the patient. Eplerenone (Inspra) may be administered with or without food.
 
Serum potassium should be measured before initiating Eplerenone (Inspra) therapy, within the first week, and at one month after the start of treatment or dose adjustment. Serum potassium should be assessed periodically thereafter.
 
For hypertensive patients receiving moderate CYP3A4 inhibitors (e.g., erythromycin, saquinavir, verapamil, and fluconazole), the starting dose of Eplerenone (Inspra) should be reduced to 25 mg once daily. In all patients taking Eplerenone (Inspra) who start taking a moderate CYP3A4 inhibitor, check serum potassium and serum creatinine in 3-7 days.
 
Hyperkalemia, dizziness, diarrhea and abdominal pain are reported side effects of Eplerenone (Inspra).
 
Try Naplex QBank. www.pharmacyexam.com